Search
01/08/2025
Renal replacement therapy modalities and techniques in intensive care units: An international survey
Monard, C, Marel, A, Joannidis, M, Ostermann, M, Peng, ZY, Doi, K, De Rosa, S, Bobek, I, Sokolov, D, Wu, VC, Premuzic, V, Mehta, R, Bellomo, R, Garcia, X, Pizarro, C, Zarbock, A, Milet, I, Reis, T, Romain, M, Mc Nicholas, B, Schneider, A, Rimmelé, T. Renal replacement therapy modalities and techniques in intensive care units: An international survey. JOURNAL OF CRITICAL CARE. 2025; 88DOI:10.1016/j.jcrc.2025.155076. PMID:40179459. IF:2.900(Q2/4D).
01/08/2025
miR-30d-5p controls hyperhomocysteinemia-related atherosclerosis through the regulation of TIMP3 and MMP9
Griñán, R, Canyelles, M, Santos, D, Alonso, J, Mallén, A, Martínez-González, J, López, S, Martinez-Perez, A, Souto, JC, Soria, JM, Sanchez-Quesada, JL, Julve, J, Rodríguez, C, Hueso, M, Blanco-Vaca, F, Rotllan, N. miR-30d-5p controls hyperhomocysteinemia-related atherosclerosis through the regulation of TIMP3 and MMP9. ATHEROSCLEROSIS. 2025; 407DOI:. PMID:. IF:5.700(Q1/1D).
01/08/2025
ESR Bridges: next-generation imaging in prostate cancer-a multidisciplinary view
Panebianco, V, Catalano, C, Sanguedolce, F, De Santis, M, Padhani, AR. ESR Bridges: next-generation imaging in prostate cancer-a multidisciplinary view. EUROPEAN RADIOLOGY. 2025; 35(8)DOI:10.1007/s00330-025-11354-1. PMID:39890618. IF:4.700(Q1/2D).
01/08/2025
Current training landscape for novice robotic surgeons: an international investigative survey by the Junior-ERUS/Young academic urologists (YAU) robotics in urology working group
Wuernschimmel, C, Wenzel, M, Moschovas, MC, Dell'Oglio, P, Paciotti, M, Bravi, CA, De Groote, R, Di Maida, F, Piramide, F, Turri, F, Andras, I, Sorce, G, Liakos, N, Breda, A, Larcher, A. Current training landscape for novice robotic surgeons: an international investigative survey by the Junior-ERUS/Young academic urologists (YAU) robotics in urology working group. WORLD JOURNAL OF UROLOGY. 2025; 43(1)DOI:10.1007/s00345-025-05845-5. PMID:40748464. IF:2.900(Q2/3D).
01/08/2025
Key strategies for reducing recurrence in T1 bladder cancer. Evidence from a retrospective multicenter European study
Contieri, R, Guigui, A, Gondran-Tellier, B, Basile, G, Zattoni, F, Gallioli, A, Verri, P, Aumatell, J, Lechevallier, E, Bastide, C, Akiki, A, Toledano, H, Moschini, M, Amparore, D, Mertens, LS, Pradere, B, Rajwa, P, Teoh, JYC, Porpiglia, F, Breda, A, Montorsi, F, Baboudjian, M, Uleri, A. Key strategies for reducing recurrence in T1 bladder cancer. Evidence from a retrospective multicenter European study. INTERNATIONAL UROLOGY AND NEPHROLOGY. 2025; 57(8)DOI:10.1007/s11255-025-04416-2. PMID:39934553. IF:1.900(Q3/6D).
01/08/2025
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial
Shore, ND, Powles, TB, Bedke, J, Galsky, MD, Redorta, JP, Ku, JH, Kretkowski, M, Xylinas, E, Alekseev, B, Ye, DW, Guerrero-Ramos, F, Briganti, A, Kulkarni, GS, Brinkmann, J, Calella, AM, Cesari, R, Eccleston, A, Michelon, E, Vermette, J, Wei, CM, Steinberg, GD. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. NATURE MEDICINE. 2025; 31(8)DOI:10.1038/s41591-025-03738-z. PMID:40450141. IF:50.000(Q1/1D).